FIH

Alimta multi cohort trial (72623)

Project Summary

Project Description
Alimta multi cohort trial
Active Substance
PHA2194694, anti-RCAI Ab
Phase of Study
Phase II/III
Primary Objective
The overall objectives are to evaluate the efficacy safety and tolerability of XDI POS in ESRD patients on hemodyalisis.
  • The primary efficacy objective is to assess the incidence of the composite of stroke, MI, CV-mortality
  • The secondary efficacy objectives are to assess the incidence of any VTE or arterial thrombosis complications
Clinical Development Plan
Clinical Research Strategy for Anetumab Ravtansine



Feasibility Analysis Progress

         Task Status Proposals / Comments # Sites # Countries Updated
Early Indic. Feasibility
Closed No new activity 70 35 14-Sep-2016 01:34pm
Protocol Feasibility
Closed No new activity 265 46 14-Sep-2016 01:34pm
Site Feasibility
Ongoing 1 NEW FOR YOU 270 55 14-Sep-2016 01:34pm



Investigator, Site & Subject Profiles